左主干冠状动脉疾病的经皮冠状动脉介入治疗（PCI）或冠状动脉旁路移植术（CABG） - Suppr | 超能文献

PCI or CABG for Left Main Coronary Artery Disease.

作者信息

Lozano Iñigo, Rondan Juan, Vegas Jose M

机构信息

Hospital de Cabueñes, Gijon, Spain

出版信息

N Engl J Med. 2020 Jul 16;383(3):290-291. doi: 10.1056/NEJMc2000645.

DOI:10.1056/NEJMc2000645

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

PCI or CABG for Left Main Coronary Artery Disease.左主干冠状动脉疾病的经皮冠状动脉介入治疗（PCI）或冠状动脉旁路移植术（CABG）

N Engl J Med. 2020 Jul 16;383(3):290-291. doi: 10.1056/NEJMc2000645.

2

Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.药物洗脱支架经皮冠状动脉介入治疗与旁路手术治疗 3 支血管病变或左主干病变患者的成本效益：紫杉醇药物洗脱支架与心脏手术（SYNTAX）试验的最终结果。

Circulation. 2014 Sep 30;130(14):1146-57. doi: 10.1161/CIRCULATIONAHA.114.009985. Epub 2014 Aug 1.

3

Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow-Up of the PRECOMBAT Trial.药物洗脱支架与冠状动脉旁路移植术治疗左主干病变的 10 年结果：PRECOMBAT 试验的扩展随访。

Circulation. 2020 May 5;141(18):1437-1446. doi: 10.1161/CIRCULATIONAHA.120.046039. Epub 2020 Mar 30.

4

Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease: A Meta-Analysis of Individual Patient Data.冠状动脉旁路移植术与药物洗脱支架置入术治疗左主干或多支冠状动脉疾病：一项个体患者数据的荟萃分析。

JACC Cardiovasc Interv. 2016 Dec 26;9(24):2481-2489. doi: 10.1016/j.jcin.2016.10.008.

5

[Comparison on the long-term outcomes post percutaneous coronary intervention or coronary artery bypass grafting for bifurcation lesions in unprotected left main coronary artery].[经皮冠状动脉介入治疗或冠状动脉旁路移植术治疗无保护左主干冠状动脉分叉病变的长期预后比较]

Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Jan 25;45(1):19-25. doi: 10.3760/cma.j.issn.0253-3758.2017.01.005.

6

Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.冠状动脉血运重建术后卒率比较：外科手术与经皮冠状动脉介入治疗。

J Am Coll Cardiol. 2018 Jul 24;72(4):386-398. doi: 10.1016/j.jacc.2018.04.071.

7

Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗三血管病变或左主干病变患者：多中心随机对照 SYNTAX 试验 10 年随访结果。

Lancet. 2019 Oct 12;394(10206):1325-1334. doi: 10.1016/S0140-6736(19)31997-X. Epub 2019 Sep 2.

8

Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.依维莫司洗脱支架或旁路移植术治疗左主干冠状动脉疾病。

N Engl J Med. 2016 Dec 8;375(23):2223-2235. doi: 10.1056/NEJMoa1610227. Epub 2016 Oct 31.

9

Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II.EXCEL 试验中依维莫司洗脱支架与冠状动脉旁路移植术治疗左主干血运重建效果的长期预测和死亡率比较：SYNTAX 评分 II 的前瞻性验证。

Eur Heart J. 2015 May 21;36(20):1231-41. doi: 10.1093/eurheartj/ehu518. Epub 2015 Jan 12.

10

Coronary artery bypass confers intermediate-term survival benefit over percutaneous coronary intervention with new-generation stents in real-world patients with multivessel coronary artery disease, including left main disease: a retrospective analysis of 6383 patients.在真实世界中患有多支冠状动脉疾病（包括左主干疾病）的患者中，冠状动脉旁路移植术相较于新一代支架的经皮冠状动脉介入治疗可带来中期生存获益：一项回顾性分析纳入了 6383 例患者。

Eur J Cardiothorac Surg. 2019 Nov 1;56(5):911-918. doi: 10.1093/ejcts/ezz142.

引用本文的文献

1

Verapamil Alleviates Myocardial Ischemia/Reperfusion Injury by Attenuating Oxidative Stress via Activation of SIRT1.维拉帕米通过激活SIRT1减轻氧化应激来缓解心肌缺血/再灌注损伤。

Front Pharmacol. 2022 Feb 23;13:822640. doi: 10.3389/fphar.2022.822640. eCollection 2022.

2

Editorial: The EXCEL Trial.社论：EXCEL 试验

Eur Cardiol. 2021 Mar 30;16:e09. doi: 10.15420/ecr.2021.02. eCollection 2021 Feb.